Skip to main content

Table 3 Demographic and clinical characteristics of the asthmatic subjects included in the study

From: Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma

Age, years (mean ± SD/range) 54 ± 11.3/36–70
Sex (male/female 6/6
Smokers/former smokers 0/0
Atopy - number (%) of patients 5 (41.6)
FEV1/FVC 64.0 ± 10.7
Post-bronchodilator FEV1 - % predicted (mean ± SD) 77.4 ± 14.7
Inhaled corticosteroids (as mcg of beclomethasone or equivalent – range) 1000–2000
Inhaled LABA (as mcg of salmeterol or equivalent – range) 200–400
Chronic oral corticosteroid use (no - % of patients) 7–58%
Daily dose of oral corticosteroids (mg of prednisone or equivalent) 21.2 ± 13.8
Intermittent oral corticosteroids (< 6 months/year) (no - % of patients) 5–42%
Previous treatment with omalizumab - number (%) of patients 5 (41.6%)
AQLQ score at baseline (mean ± SD), 0–4 point scale 2.9 ± 0.9
ACQ score at baseline (mean ± SD), 0–7 point scale 4.7 ± 0,8
Exacerbation/patient/year (12 months before recruitment) 4.7 ± 2.0
Hospitalizations/patient/year (12 months before recruitment) 1.2 ± 1.7
Days lost of work/patient/year (12 months before recruitment) 27.2 ± 21.3